Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Germ Cell and Embryonal » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Neuroectodermal Tumors, Primitive » Neuroectodermal Tumors, Primitive, Peripheral » Neuroblastoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Neoplasms, Neuroepithelial » Neuroectodermal Tumors, Primitive » Neuroectodermal Tumors, Primitive, Peripheral » Neuroblastoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Nerve Tissue » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Neuroectodermal Tumors, Primitive » Neuroectodermal Tumors, Primitive, Peripheral » Neuroblastoma
Description
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) MeSH
Hierarchy View
Subtype Terms (2)
Esthesioneuroblastoma, Olfactory
1 experimental drug
Ganglioneuroblastoma
24 drugs (21 approved, 3 experimental)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (33)
Phase 2 Indicated Drugs (100)
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous mononuclear stem cell
Phase 1 Indicated Drugs (97)
14g2a.zeta chimeric receptor transduced autologous ebv specific cytotoxic t-lymphocytes
allogeneic neuroblastoma cells
anti-ny eso-1 tcr-transduced t cells
autologous dendritic cells loaded with autologous tumor lysate
autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine
ex vivo activated immune cells
gene modified neuroblastoma cells
interferon gamma-1b (actimmune)
mage-a1, mage-a3, and ny-eso-1 vaccine
Other Experimental Indicated Drugs (15)
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (32)
Children's Cancer and Leukaemia Group
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Mercy Regional Cancer Center at Mercy Medical Center
Oregon Health and Science University
Royal Marsden Hospital NHS Trust
Organization Involved with Phase 2 Indications (104)
Advanced Accelerator Applications
Arnold Palmer Hospital for Children
Bambino Gesù Hospital and Research Institute
Cancer Prevention Pharmaceuticals, Inc.
Cancer Treatment Centers of America
Case Western Reserve University
Catholic University of Sacred Heart, Rome
Centre Hospitalier Regional de Purpan
City of Hope National Medical Center
European Infant Neuroblastoma Study Group - 1999
Laboratorio Elea S.A.C.I.F. y A.
Memorial Sloan-Kettering Cancer Center
Molecular Insight Pharmaceuticals
National Cancer Institute, France
National Center for Research Resources (NCRR)
National Institutes of Health (NIH)
National University of Singapore
Neuroblastoma and Medulloblastoma Translational Research Consortium
Shenzhen Geno-Immune Medical Institute
Societe Francaise Oncologie Pediatrique
State University of New York, Buffalo
University of California, Davis
Organization Involved with Phase 1 Indications (60)
Alex's Lemonade Stand Foundation
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Ben Towne Center for Childhood Cancer Research
Cancer Immunotherapy Trials Network
Catherine Elizabeth Blair Memorial Foundation
Children's Hospital Los Angeles
Children's Hospital of Philadelphia
Developmental Therapeutics Consortium
Evan T.J. Dunbar Neuroblastoma Foundation
Methodist Cancer Center, Houston, Texas
Midwest Athletes Against Childhood Cancer, Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Pediatric Brain Tumor Consortium
Shenzhen Institute for Innovation and Translational Medicine
SignalRX Pharmaceuticals, Inc.
Organization Involved with Other Experimental Indications (11)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
